Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

BEECHTREE DIAGNOSTICS LLP

NPI: 1215302245 · DRAPER, UT 84020 · Clinical Medical Laboratory · NPI assigned 12/02/2015

$34.70M
Total Medicaid Paid
614,049
Total Claims
289,469
Beneficiaries
38
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialDAWSON, GARY (VP OF FINANCE)
Parent OrganizationLABPARTNER LLC
NPI Enumeration Date12/02/2015

Related Entities

Other providers sharing the same authorized official: DAWSON, GARY

ProviderCityStateTotal Paid
BEECHTREE MOLECULAR LAB LLC DRAPER UT $863K
RIVERCITY REHABILITATION AND SPINE SPECIALISTS, P.C. COLUMBUS GA $179K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 21,292 $1.13M
2019 109,094 $5.95M
2020 76,552 $6.31M
2021 87,008 $4.89M
2022 120,592 $5.53M
2023 100,164 $5.92M
2024 99,347 $4.97M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 140,887 79,198 $21.12M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 280,397 115,305 $6.26M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 43,855 24,062 $3.25M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 33,219 15,348 $2.68M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 9,115 3,040 $1.39M
83789 26,623 13,236 $495.29
82542 26,621 13,235 $355.60
80364 1,052 533 $112.75
83992 1,050 532 $99.30
80356 1,040 525 $0.00
80337 1,050 532 $0.00
80365 1,052 533 $0.00
80325 987 503 $0.00
80361 1,052 533 $0.00
80373 1,050 532 $0.00
80346 807 366 $0.00
80372 1,052 532 $0.00
80370 1,050 532 $0.00
80355 1,048 531 $0.00
80375 1,052 533 $0.00
80323 1,042 528 $0.00
80354 1,050 532 $0.00
80348 1,048 531 $0.00
80342 1,050 532 $0.00
80347 231 161 $0.00
80360 1,051 533 $0.00
80334 1,049 532 $0.00
80366 1,051 533 $0.00
80368 1,047 530 $0.00
80345 1,050 533 $0.00
80353 1,050 532 $0.00
80358 1,050 532 $0.00
80371 1,043 528 $0.00
80340 1,050 532 $0.00
80357 1,028 516 $0.00
80349 1,051 533 $0.00
80177 22,999 10,678 $0.00
80359 1,050 532 $0.00